Ironwood Pharmaceuticals, Inc. (IRWD) trades at a trailing P/E of 23.1, forward P/E of 3.2. Trailing earnings yield is 4.34%, forward earnings yield 31.65%. PEG 0.02 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 54/100 with 0/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -27.1 | 0.62 | 33.21 | 8.09 | - |
| 2017 | -19.0 | -0.46 | 225.91 | 7.46 | - |
| 2018 | -5.6 | -0.04 | -8.05 | 4.56 | - |
| 2019 | 96.6 | -1.02 | -22.27 | 4.85 | - |
| 2020 | 17.1 | -0.02 | 28.99 | 4.66 | - |
| 2021 | 3.6 | 0.01 | 3.12 | 4.57 | - |
| 2022 | 10.9 | -0.17 | 2.93 | 4.66 | - |
| 2023 | -1.8 | 0.00 | -5.13 | 4.02 | - |
| 2024 | 800.8 | -8.00 | -2.34 | 2.01 | - |
| 2025 | 22.8 | 0.01 | -2.09 | 1.85 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-0.56 | $273.96M | $-81.71M | -29.8% |
| 2017 | $-0.78 | $298.28M | $-116.94M | -39.2% |
| 2018 | $-1.85 | $346.64M | $-282.37M | -81.5% |
| 2019 | $-0.10 | $428.41M | $-15.31M | -3.6% |
| 2020 | $0.66 | $389.52M | $106.18M | 27.3% |
| 2021 | $3.21 | $413.75M | $528.45M | 127.7% |
| 2022 | $0.94 | $410.6M | $175.07M | 42.6% |
| 2023 | $-6.45 | $442.74M | $-1B | -226.4% |
| 2024 | $0.01 | $351.41M | $880K | 0.3% |
| 2025 | $0.15 | $296.15M | $24.02M | 8.1% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $1.28 | $1.26 – $1.30 | $460.14M | $454.89M – $465.26M | 2 |
| 2027 | $1.35 | $1.33 – $1.37 | $476.61M | $471.18M – $481.91M | 2 |
| 2028 | $1.56 | $1.54 – $1.58 | $485.51M | $483.24M – $487.77M | 1 |
| 2029 | $0.48 | $0.47 – $0.49 | $253.3M | $250.41M – $256.12M | 1 |
| 2030 | $0.61 | $0.60 – $0.61 | $236.93M | $234.23M – $239.56M | 1 |
